Pasithea Therapeutics (NASDAQ:KTTA) was upgraded by analysts at Zacks Research to a "hold" rating.
Pasithea Therapeutics (NASDAQ:KTTA) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Pasithea Therapeutics (NASDAQ:KTTA) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.
Pasithea Therapeutics (NASDAQ:KTTA) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.
Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock